Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2015

01-12-2015 | Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review

Alcohol and the HIV Continuum of Care

Authors: Panagiotis Vagenas, Marwan M. Azar, Michael M. Copenhaver, Sandra A. Springer, Patricia E. Molina, Frederick L. Altice

Published in: Current HIV/AIDS Reports | Issue 4/2015

Login to get access

Abstract

Alcohol use is highly prevalent globally with numerous negative consequences to human health, including HIV progression, in people living with HIV (PLH). The HIV continuum of care, or treatment cascade, represents a sequence of targets for intervention that can result in viral suppression, which ultimately benefits individuals and society. The extent to which alcohol impacts each step in the cascade, however, has not been systematically examined. International targets for HIV treatment as prevention aim for 90 % of PLH to be diagnosed, 90 % of them to be prescribed with antiretroviral therapy (ART), and 90 % to achieve viral suppression; currently, only 20 % of PLH are virally suppressed. This systematic review, from 2010 through May 2015, found 53 clinical research papers examining the impact of alcohol use on each step of the HIV treatment cascade. These studies were mostly cross-sectional or cohort studies and from all income settings. Most (77 %) found a negative association between alcohol consumption on one or more stages of the treatment cascade. Lack of consistency in measurement, however, reduced the ability to draw consistent conclusions. Nonetheless, the strong negative correlations suggest that problematic alcohol consumption should be targeted, preferably using evidence-based behavioral and pharmacological interventions, to indirectly increase the proportion of PLH achieving viral suppression, to achieve treatment as prevention mandates, and to reduce HIV transmission.
Literature
1.
2.
Report G. UNAIDS report on the global AIDS epidemic. Geneva: UNAIDS; 2012.
3.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCentralCrossRefPubMed
4.
5.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.CrossRefPubMed
6.
Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.PubMedCentralCrossRefPubMed
7.••
INSIGHT START Study Group, Lundgren JD, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807. The START trial showed that early initiation of antiretroviral therapy (CD4+ count >500) provided net benefits over starting therapy after the CD4+ was <350.CrossRef
8.•
Stahre M, Roeber J, Kanny D, Brewer RD, Zhang X. Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. Prev Chronic Dis. 2014;11:E109. Excessive drinking accounts for 1 in 10 deaths among working-age adults in the USA.PubMedCentralCrossRefPubMed
9.
Results from the 2013 National Survey on Drug Use and Health: summary of national findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014
10.
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.CrossRefPubMed
11.
Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res. 2010;85(1):303–15.CrossRefPubMed
12.
Petry NM. Alcohol use in HIV patients: what we don’t know may hurt us. Int J STD AIDS. 1999;10(9):561–70.CrossRefPubMed
13.
Scott-Sheldon LA, Carey KB, Cunningham K, Johnson BT, Carey MP, MASH Research Team. Alcohol use predicts sexual decision-making: a systematic review and meta-analysis of the experimental literature. AIDS Behav. 2015 (in press).
14.
Scott-Sheldon LA, Walstrom P, Carey KB, Johnson BT, Carey MP, MASH Research Team. Alcohol use and sexual risk behaviors among individuals infected with HIV: a systematic review and meta-analysis 2012 to early 2013. Curr HIV/AIDS Rep. 2013;10(4):314–23.PubMedCentralCrossRefPubMed
15.
Zarkin GA, Bray JW, Babor TF, Higgins-Biddle JC. Alcohol drinking patterns and health care utilization in a managed care organization. Health Serv Res. 2004;39(3):553–70.PubMedCentralCrossRefPubMed
16.
Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112(3):178–93.PubMedCentralCrossRefPubMed
17.
Anand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav. 2010;14(6):1213–26.PubMedCentralCrossRefPubMed
18.
Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on cognitive function in HIV infection. Am J Psychiatry. 2004;161(2):249–54.CrossRefPubMed
19.
Ajithkumar K, Neera PG, Rajani PP. Relationship between social factors and treatment adherence: a study from South India. Eastern J Med. 2011;16(2):147–52.
20.
Alemu H, Mariam DH, Tsui AO, Shewamare A. Correlates of highly active antiretroviral therapy adherence among urban Ethiopian clients. Afr J AIDS Res. 2011;10(3):263–70.CrossRefPubMed
21.
22.
Bhat VG, Ramburuth M, Singh M, Titi O, Antony AP, Chiya L, et al. Factors associated with poor adherence to anti-retroviral therapy in patients attending a rural health centre in South Africa. Eur J Clin Microbiol Infect Dis. 2010;29(8):947–53.CrossRefPubMed
23.
Broyles LM, Gordon AJ, Sereika SM, Ryan CM, Erlen JA. Predictive utility of brief Alcohol Use Disorders Identification Test (AUDIT) for human immunodeficiency virus antiretroviral medication nonadherence. Subst Abus. 2011;32(4):252–61.PubMedCentralCrossRefPubMed
24.
Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, et al. Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS Behav. 2013;17 Suppl 2:S118–S27.CrossRefPubMed
25.
Conen A, Wang Q, Glass TR, Fux CA, Thurnheer MC, Orasch C, et al. Association of alcohol consumption and HIV surrogate markers in participants of the Swiss HIV cohort study. J Acquir Immune Defic Syndr. 2013;64(5):472–8.CrossRefPubMed
26.
Farley J, Miller E, Zamani A, Tepper V, Morris C, Oyegunle M, et al. Screening for hazardous alcohol use and depressive symptomatology among HIV-infected patients in Nigeria: prevalence, predictors, and association with adherence. J Int Assoc Physicians AIDS Care. 2010;9(4):218–26.CrossRef
27.•
Ferro EG, Weikum D, Vagenas P, Copenhaver MM, Gonzales P, Peinado J, et al. Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru. AIDS Care. 2015;27(1):93–104. This study demonstrates that AUDs are associated with sub-optimal adherence among HIV-infected MSM.CrossRefPubMed
28.
Freeman A, Newman J, Hemingway-Foday J, Iriondo-Perez J, Stolka K, Akam W, et al. Comparison of HIV-positive women with children and without children accessing HIV care and treatment in the IeDEA Central Africa cohort. AIDS Care. 2012;24(6):673–9.CrossRefPubMed
29.
Harris J, Pillinger M, Fromstein D, Gomez B, Garris PA, Kanetsky PA, et al. Risk factors for medication non-adherence in an HIV infected population in the Dominican Republic. AIDS Behav. 2011;15(7):1410–5.PubMedCentralCrossRefPubMed
30.
Jaquet A, Ekouevi DK, Bashi J, Aboubakrine M, Messou E, Maiga M, et al. Alcohol use and non-adherence to antiretroviral therapy in HIV-infected patients in West Africa. Addiction. 2010;105(8):1416–21.CrossRefPubMed
31.
Jones AS, Lillie-Blanton M, Stone VE, Ip EH, Zhang Q, Wilson TE, et al. Multi-dimensional risk factor patterns associated with non-use of highly active antiretroviral therapy among human immunodeficiency virus-infected women. Womens Health Issues. 2010;20(5):335–42.PubMedCentralCrossRefPubMed
32.
Kalichman SC, Amaral CM, White D, Swetsze C, Kalichman MO, Cherry C, et al. Alcohol and adherence to antiretroviral medications: interactive toxicity beliefs among people living with HIV. J Assoc Nurses AIDS Care. 2012;23(6):511–20.PubMedCentralCrossRefPubMed
33.
Kalichman SC, Cherry C, White D, Jones M, Grebler T, Kalichman MO, et al. Sexual HIV transmission and antiretroviral therapy: a prospective cohort study of behavioral risk factors among men and women living with HIV/AIDS. Ann Behav Med. 2011;42(1):111–9.CrossRefPubMed
34.
Kalichman SC, Grebler T, Amaral CM, McNerey M, White D, Kalichman MO, et al. Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs. J Gen Intern Med. 2013;28(3):399–405.PubMedCentralCrossRefPubMed
35.
Kalichman SC, Grebler T, Amaral CM, McNerney M, White D, Kalichman MO, et al. Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adults. Int J Behav Med. 2014;21(5):811–20.PubMedCentralCrossRefPubMed
36.
Kekwaletswe CT, Morojele NK. Patterns and predictors of antiretroviral therapy use among alcohol drinkers at HIV clinics in Tshwane, South Africa. AIDS Care. 2014;26 Suppl 1:78–82.CrossRef
37.
Kenya S, Chida N, Jones J, Alvarez G, Symes S, Kobetz E. Weekending in PLWH: alcohol use and ART adherence. Pilot Stud AIDS Behavior. 2013;17(1):61–7.CrossRef
38.
Kowalski S, Colantuoni E, Lau B, Keruly J, McCaul ME, Hutton HE, et al. Alcohol consumption and CD4 T-cell count response among persons initiating antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;61(4):455–61.PubMedCentralCrossRefPubMed
39.
Kozak MS, Mugavero MJ, Ye JT, Aban I, Lawrence ST, Nevin CR, et al. Patient reported outcomes in routine care: advancing data capture for HIV cohort research. Clin Infect Dis. 2012;54(1):141–7.PubMedCentralCrossRefPubMed
40.
Kreitchmann R, Harris DR, Kakehasi F, Haberer JE, Cahn P, Losso M, et al. Antiretroviral adherence during pregnancy and postpartum in Latin America. AIDS Patient Care STDS. 2012;26(8):486–95.PubMedCentralCrossRefPubMed
41.
Malbergier A, Do Amaral RA, Cardoso LD. Alcohol dependence and CD4 cell count: is there a relationship? AIDS Care. 2015;27(1):54–8.CrossRefPubMed
42.
Marks King R, Vidrine DJ, Danysh HE, Fletcher FE, McCurdy S, Arduino RC, et al. Factors associated with nonadherence to antiretroviral therapy in HIV-positive smokers. AIDS Patient Care STDS. 2012;26(8):479–85.PubMedCentralCrossRef
43.
Medley A, Seth P, Pathak S, Howard AA, DeLuca N, Matiko E, et al. Alcohol use and its association with HIV risk behaviors among a cohort of patients attending HIV clinical care in Tanzania, Kenya, and Namibia. AIDS Care. 2014;26(10):1288–97.CrossRefPubMed
44.
Morojele NK, Kekwaletswe CT, Nkosi S. Associations between alcohol use, other psychosocial factors, structural factors and antiretroviral therapy (ART) adherence among South African ART recipients. AIDS Behav. 2014;18(3):519–24.CrossRefPubMed
45.
Parsons JT, Starks TJ, Millar BM, Boonrai K, Marcotte D. Patterns of substance use among HIV-positive adults over 50: implications for treatment and medication adherence. Drug Alcohol Depend. 2014;139:33–40.PubMedCentralCrossRefPubMed
46.
Rosen MI, Black AC, Arnsten JH, Goggin K, Remien RH, Simoni JM, et al. Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. AIDS Behav. 2013;17(1):142–7.PubMedCentralCrossRefPubMed
47.
Sharma A, Sachdeva RK, Kumar M, Nehra R, Nakra M, Jones D. Effects of lifetime history of use of problematic alcohol on HIV medication adherence. J Int Assoc Provid AIDS Care. 2014;13(5):450–3.CrossRefPubMed
48.
Teixeira C, Dourado MDL, Santos MP, Brites C. Impact of use of alcohol and illicit drugs by AIDS patients on adherence to antiretroviral therapy in Bahia. Brazil AIDS Res Hum Retroviruses. 2013;29(5):799–804.CrossRefPubMed
49.
Venkatesh KK, Srikrishnan AK, Mayer KH, Kumarasamy N, Raminani S, Thamburaj E, et al. Predictors of nonadherence to highly active antiretroviral therapy among HIV-infected South Indians in clinical care: implications for developing adherence interventions in resource-limited settings. AIDS Patient Care STDS. 2010;24(12):795–803.PubMedCentralCrossRefPubMed
50.•
Woolf-King SE, Neilands TB, Dilworth SE, Carrico AW, Johnson MO. Alcohol use and HIV disease management: the impact of individual and partner-level alcohol use among HIV-positive men who have sex with men. AIDS Care. 2014;26(6):702–8. Hazardous drinkers were shown to be less likely to achieve viral suppression, compared to non-drinkers.PubMedCentralCrossRefPubMed
51.
Carrieri MP, Protopopescu C, Raffi F, March L, Reboud P, Spire B, et al. Low alcohol consumption as a predictor of higher CD4+ cell count in HIV-treated patients: a French paradox or a proxy of healthy behaviors? The ANRS APROCO-COPILOTE CO-08 cohort. J Acquir Immune Defic Syndr. 2014;65(4):e148–e50.CrossRefPubMed
52.
Dahab M, Charalambous S, Karstaedt AS, Fielding KL, Hamilton R, La Grange L, et al. Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. BMC Public Health. 2010;10.
53.
Iralu J, Duran B, Pearson CR, Jiang Y, Foley K, Harrison M. Risk factors for HIV disease progression in a rural southwest American Indian population. Public Health Rep. 2010;125 Suppl 4:43–50.PubMedCentralPubMed
54.•
Kader R, Seedat S, Govender R, Koch JR, Parry CD. Hazardous and harmful use of alcohol and/or other drugs and health status among South African patients attending HIV clinics. AIDS Behav. 2014;18(3):525–34. This study shows that hazardous/harmful drinkers are less likely to be prescribed with ART.CrossRefPubMed
55.
Kalichman SC, Grebler T, Amaral CM, McKerey M, White D, Kalichman MO, et al. Assumed infectiousness, treatment adherence and sexual behaviours: applying the Swiss Statement on infectiousness to HIV-positive alcohol drinkers. HIV Med. 2013;14(5):263–72.PubMedCentralCrossRefPubMed
56.
Lima VD, Kerr T, Wood E, Kozai T, Salters KA, Hogg RS, et al. The effect of history of injection drug use and alcoholism on HIV disease progression. AIDS Care. 2014;26(1):123–9.CrossRefPubMed
57.
Marcellin F, Lions C, Winnock M, Salmon D, Durant J, Spire B, et al. Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician’s perceptions (HEPAVIH ARNS CO13 cohort). Addiction. 2013;108(7):1250–8.CrossRefPubMed
58.
McMahon JH, Manoharan A, Wanke C, Mammen S, Jose H, Malini T, et al. Targets for intervention to improve virological outcomes for patients receiving free antiretroviral therapy in Tamil Nadu, India. AIDS Care. 2014;26(5):559–66.CrossRefPubMed
59.
Shacham E, Agbebi A, Stamm K, Overton ET. Alcohol consumption is associated with poor health in HIV clinic patient population: a behavioral surveillance study. AIDS Behav. 2011;15(1):209–13.PubMedCentralCrossRefPubMed
60.
Skeer MR, Mimiaga MJ, Mayer KH, O’Cleirigh C, Covahey C, Safren SA. Patterns of substance use among a large urban cohort of HIV-infected men who have sex with men in primary care. AIDS Behav. 2012;16(3):676–89.PubMedCentralCrossRefPubMed
61.
Sullivan KA, Messer LC, Quinlivan EB. Substance abuse, violence, and HIV/AIDS (SAVA) syndemic effects on viral suppression among HIV positive women of color. AIDS Patient Care STDS. 2015;29 Suppl 1:S42–8.CrossRefPubMed
62.
63.
Bengtson AM, L’Engle K, Mwarogo P, King’ola N. Levels of alcohol use and history of HIV testing among female sex workers in Mombasa, Kenya. AIDS Care. 2014;26(12):1619–24.PubMedCentralCrossRefPubMed
64.
Fatch R, Bellows B, Bagenda F, Mulogo E, Weiser S, Hahn JA. Alcohol consumption as a barrier to prior HIV testing in a population-based study in rural Uganda. AIDS Behav. 2013;17(5):1713–23.PubMedCentralCrossRefPubMed
65.•
Vagenas P, Ludford KT, Gonzales P, Peinado J, Cabezas C, Gonzales F, et al. Being unaware of being HIV-infected is associated with alcohol use disorders and high-risk sexual behaviors among men who have sex with men in Peru. AIDS Behav. 2014;18(1):120–7. This study with a large sample of MSM in Peru showed that AUDs are associated with being unaware of being HIV infected.CrossRefPubMed
66.
Althoff AL, Zelenev A, Meyer JP, Fu J, Brown SE, Vagenas P, et al. Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav. 2013;17 Suppl 2:S156–70.CrossRefPubMed
67.
Lifson AR, Demissie W, Tadesse A, Ketema K, May R, Yakob B, et al. Barriers to retention in care as perceived by persons living with HIV in rural Ethiopia: focus group results and recommended strategies. J Int Assoc Provid AIDS Care. 2013;12(1):32–8.CrossRefPubMed
68.
Pecoraro A, Mimiaga M, O’Cleirigh C, Safren SA, Blokhina E, Verbitskaya E, et al. Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian Federation. AIDS Care. 2015;27(1):86–92.CrossRefPubMed
69.
Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56 Suppl 1:S22–32.PubMedCentralCrossRefPubMed
70.
Neblett RC, Hutton HE, Lau B, McCaul ME, Moore RD, Chander G. Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival. J Womens Health. 2011;20(2):279–86.CrossRef
71.
Santos GM, Emenyonu NI, Bajunirwe F, Rain Mocello A, Martin JN, Vittinghoff E, et al. Self-reported alcohol abstinence associated with ART initiation among HIV-infected persons in rural Uganda. Drug Alcohol Depend. 2014;134(1):151–7.CrossRefPubMed
72.
Babor TF, Delafuente JR, Saunders J. AUDIT: the Alcohol Use Disorders Identification Test: guidelines for use in primary health care. Geneva: World Health Organization; 1992.
73.
74.
WHO. Global status report on alcohol and health. Geneva: World Health Organization; 2014.
75.••
Lourenco L, Hull M, Nosyk B, Montaner JSG, Lima VD. The need for standardisation of the HIV continuum of care. Lancet HIV. 2015;2(6):e225–e6. This paper describes how stages of the HIV continuum of care are defined differently in different locations and urges for standardization across the world.CrossRefPubMed
76.
Pineirua A, Sierra-Madero J, Cahn P, Guevara Palmero RN, Martinez Buitrago E, Young B, et al. The HIV care continuum in Latin America: challenges and opportunities. Lancet Infect Dis. 2015;15(7):833–9.CrossRefPubMed
77.
Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Internal Medicine. 2015;175(4):588–96.CrossRefPubMed
78.
Parchure R, Kulkarni V, Kulkarni S, Gangakhedkar R. Pattern of linkage and retention in HIV care continuum among patients attending referral HIV care clinic in private sector in India. AIDS Care. 2015;27(6):716–22.CrossRefPubMed
79.
Bradley H, Hall HI, Wolitski RJ, Van Handel MM, Stone AE, LaFlam M, et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV—United States, 2011. MMWR Morb Mortal Wkly Rep. 2014;63(47):1113–7.PubMed
80.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789–95.CrossRefPubMed
81.
McLellan AT, Cacciola JC, Alterman AI, Rikoon SH, Carise D. The Addiction Severity Index at 25: origins, contributions and transitions. Am J Addict. 2006;15(2):113–24.CrossRefPubMed
82.
Palepu A, Milloy MJ, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Health. 2011;88(3):545–55.PubMedCentralCrossRefPubMed
83.
Anema A, Weiser SD, Fernandes KA, Ding E, Brandson EK, Palmer A, et al. High prevalence of food insecurity among HIV-infected individuals receiving HAART in a resource-rich setting. AIDS Care. 2011;23(2):221–30.CrossRefPubMed
84.
Mugavero MJ, Amico KR, Westfall AO, Crane HM, Zinski A, Willig JH, et al. Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention. J Acquir Immune Defic Syndr. 2012;59(1):86–93.PubMedCentralCrossRefPubMed
85.
Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, et al. Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. J Infect Dis. 2013;207(5):759–67.CrossRefPubMed
86.
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2013;6(3):249–69.PubMedCentralCrossRefPubMed
87.
Ing EC, Bae JW, Maru DS, Altice FL. Medication persistence of HIV-infected drug users on directly administered antiretroviral therapy. AIDS Behav. 2013;17(1):113–21.CrossRefPubMed
88.
NIMH Collaborative HIV/STD Prevention Trial Group. Sexually transmitted disease and HIV prevalence and risk factors in concentrated and generalized HIV epidemic settings. AIDS. 2007;21 Suppl 2:S81–90.CrossRef
89.
WHO. Global status report on alcohol and health. Geneva: World Health Organization; 2011.
90.
World Health Organization (WHO). International guide for monitoring alcohol consumption and related harm. Geneva: Dependence DoMHaS; 2000.
91.
Lourenço L, Hull M, Nosyk B, Montaner JS, Lima VD. The need for standardisation of the HIV continuum of care. Lancet HIV. 2015;2:e225–6.CrossRefPubMed
92.
Kamarulzaman A, Altice FL. Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis. 2015;28(1):10–6.CrossRefPubMed
93.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.PubMedCentralCrossRefPubMed
94.
Stevens W, Gous N, Ford N, Scott LE. Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions. BMC Med. 2014;12:173.PubMedCentralCrossRefPubMed
95.
MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345, e5945.PubMedCentralCrossRefPubMed
96.
Edelman EJ, Chantarat T, Caffrey S, Chaudhry A, O’Connor PG, Weiss L, et al. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug Alcohol Depend. 2014;139:79–85.PubMedCentralCrossRefPubMed
97.
Klimas J, Tobin H, Field CA, O’Gorman CS, Glynn LG, Keenan E, et al. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Cochrane Database Syst Rev. 2014;12, CD009269.PubMed
98.
Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17.CrossRefPubMed
99.
Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res. 2011;35:1804–11.CrossRefPubMed
100.
O’Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol. 2007;27(5):507–12.CrossRefPubMed
101.
Garbutt JC, Kranzler HR, O’Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617–25.CrossRefPubMed
102.
Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–900.CrossRefPubMed
103.
Brown SE, Vagenas P, Konda KA, Clark JL, Lama JR, Gonzales P, et al. Men who have sex with men in Peru: acceptability of medication-assisted therapy for treating alcohol use disorders. Am J Mens Health. 2015 (in press).
104.
Copenhaver MM, Tunku N, Ezeabogu I, Potrepka J, Zahari MM, Kamarulzaman A, et al. Adapting an evidence-based intervention targeting HIV-infected prisoners in Malaysia. AIDS Res Treat. 2011;2011, 131045.PubMedCentralPubMed
105.
Armstrong ML, LaPlante AM, Altice FL, Copenhaver MM, Molina PE. Advancing behavioral HIV prevention: adapting an evidence-based intervention for people living with HIV and alcohol use disorders. AIDS Research and Treatment. 2015 (in press).
106.
Centers for Disease Control and Prevention. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2012;61(RR-5):1–40.
107.
WHO/UNODC/UNAIDS. Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach 2008. December 16, 2008. Available at http://​whqlibdoc.​who.​int/​publications/​2008/​9789241596930_​eng.​pdf.​ Accessed 16 Dec 2008.
Metadata
Title
The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review
Alcohol and the HIV Continuum of Care
Authors
Panagiotis Vagenas
Marwan M. Azar
Michael M. Copenhaver
Sandra A. Springer
Patricia E. Molina
Frederick L. Altice
Publication date
01-12-2015
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 4/2015
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-015-0285-5

Other articles of this Issue 4/2015

Current HIV/AIDS Reports 4/2015 Go to the issue

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Tobacco Use, Use Disorders, and Smoking Cessation Interventions in Persons Living With HIV

HIV and Technology (J Simoni and K Horvath, Section Editors)

Technology-Delivered Mental Health Interventions for People Living with HIV/AIDS (PLWHA): a Review of Recent Advances

HIV and Technology (J Simoni and K Horvath, Section Editors)

Use of Technology for HIV Prevention Among Adolescent and Adult Women in the United States

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

HIV and Technology (J Simoni and K Horvath, Section Editors)

The Use of Technology to Advance HIV Prevention for Couples

HIV and Technology (J Simoni and K Horvath, Section Editors)

Evidence for Technology Interventions to Promote ART Adherence in Adult Populations: a Review of the Literature 2012–2015

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits